Hariprasad Vankayalapati, M. Pharm., PhD. Chief Scientific Officer & Founder
Dr. Hari is a Founder of Arrien Pharmaceuticals, currently serving as Chief Scientific Officer & Scientific Advisory Board Member of the Company. Dr. Hari has held position of increasing responsibility on developing the FIELDS technology. He then successfully translated the FIELD technology and executed the early/discovery and development of pipeline of targeted therapeutics for Cancer, Inflammation, Autoimmune, CNS/Neurodegenerative and Diabesity diseases. Currently he is serving as Assistant Professor/Chief Scientist of Medicinal Chemistry at the Center for Investigational Therapeutics (CIT) of The Huntsman Cancer Institute & School of Medicine of University Of Utah in Salt Lake City. His focus mainly on early Discovery to IND stage of Development of novel therapeutics. From 2006-2009 Dr. Hari served as Chief Scientist at the SuperGen/Astex (now Otsuka Pharmaceuticals). From 2003-2006 he was serving as Program Director of Medicinal Chemistry for early Discovery/Development and was key in creating several pipeline of pre-clinical programs, CLIMB technology and co-founded Montigen Pharmaceuticals in year 2003 with an initial Series B rise of 5 million. Later in year 2006 Montigen was acquired by SuperGen Inc., for 40 million where Dr. Hari played a key role in bringing science/technology in this deal transaction.
Dr. Hari’s involvement over the years in Drug Discovery/Development, and his leadership lead to the discovery of first-in-class three clinical drug candidates; Amuvatinib/MP-470, SGI-1776 and S-110 (Guadecitabine) entered into clinical Phase I, II & III trials. He is an author of more than 70 peer reviewed scientific publications & presentations in Medicinal, Organic, Computational Chemistry and Drug Discovery areas. He is an inventor of over 23 published/issued US/WO patents. He holds Ph.D. and M. Pharm degrees in Medicinal Chemistry from the Institute of Chemical Technology (formally UDCT) of University of Mumbai and University of Karnatk in India. He completed his Post-Doctoral training in Organic Chemistry from University of Sunderland in England and Medicinal Chemistry from University of Arizona Cancer Center, USA.
Rajendra P. Appalaneni, B. Pharm Chairman & Co-Founder
Mr. Rajendra P. Appalaneni co-founded Arrien Pharmaceuticals, LLC in 2011 and currently serving as Chairman and Board of Directors of the company. Mr. Appalaneni also serving as Chairman, President of Appco Pharma, a generic Pharmaceutical manufacturing company located in NJ and was a Co-Founder of Alveus Pharmaceuticals. He is working as Maryland licensed Pharmacist, Member NCPA, Board member of CT Pharmacist's Association (CPA), and he was a board of directors of Computer Analysts Corp. NY, CT.